Company: CERO
Filing Date: 2025-02-12
Form Type: 8-K
Source: 0001213900-25-012891
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On February 12, 2025, CERo Therapeutics Holdings,
Inc. (the “ Company”) received a letter from the Nasdaq Stock Market LLC (“ Nasdaq”) confirming that the Company
has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Requirement”)
and has applied and been moved to the Nasdaq Capital Market, as required by the panel convened by Nasdaq (the “ Nasdaq Panel”).

Regaining compliance with the Bid Price Requirement
is one of the conditions set forth by the Nasdaq Panel in its previously disclosed decision granting the Company’s request for an
extension (the “ Extension”) to regain compliance with certain Nasdaq continued listing requirements until April 22, 2025.
The Company continues to make progress towards satisfaction of the other conditions.

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

  Date: February 12, 2025      CERO THERAPEUTICS HOLDINGS, INC.                               
 ──────────────────────────────────────────────────────────────────────────────────────────────
                               By:                                   /s/ Chris Ehrlich        
                               Name:                                 Chris Ehrlich            
                               Title:                                Chief Executive Officer